Efgartigimod active on different muscle groups in myasthenia gravis

A post-hoc analysis of the results of the Adapt trial, which was conducted in France in 167 adults with a generalised form of autoimmune myasthenia gravis, showed that efgartigimod resulted in :

• an improvement, greater than on placeboLe placebo est un produit dont la présentation est identique à celle d’un médicament, mais qui ne contient pas de principe actif. Dans un essai clinique, un placebo est utilisé pour mesurer l’action réelle du médicament testé, en comparant les effets du médicament testé contenant le principe actif et ceux du placebo., in each of the muscle sub-domains (respiratory, ocular, bulbar, limb) assessed by the MG-ADL score,
• observed from one to two weeks after the first infusion and correlated with the reduction in IgG levels.

These results complement those published in 2021 and early 2023, which reported an overall improvement in the MG-ADL score and quality of life.

Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study. Bril V, Howard JF Jr, Karam C et al. Eur J Neurol. 2023 Oct 16.